Abstract

Long-acting antimuscarinics (LAMA) are a first-line option for patients with chronic obstructive pulmonary disease (COPD) who are symptomatic or at

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call